The Global Cancer Cachexia Market, valued at USD 2.84 Billion in 2025, is projected to exhibit a CAGR of 6.6%, reaching USD 4.44 Billion by 2032.
The market growth is primarily driven by the increasing prevalence of cancer-related wasting syndromes, rising awareness of cachexia as a distinct clinical condition, and growing adoption of multimodal treatment approaches. Advancements in pharmacological therapies targeting inflammatory pathways, appetite stimulation, and muscle preservation are contributing to improved management outcomes.
Additionally, ongoing clinical trials exploring anabolic agents, cytokine inhibitors, and metabolic modulators, along with supportive care integration and early diagnosis initiatives, are expected to further accelerate the market expansion over the forecast period.
Market Takeaways
Global Cancer Cachexia Market Report Coverage
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/cancer-cachexia-market
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 2.84 Billion |
|
Estimated Value by 2032 |
USD 4.44 Billion |
|
Growth Rate |
Poised to exhibit a CAGR of 6.6% |
|
Historical Data |
2020-2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Trends |
|
|
Opportunities |
|
|
Restraints & Challenges |
|
Market Dynamics
The global cancer cachexia market is witnessing steady growth, driven by the rising prevalence of advanced-stage cancers, increasing recognition of cachexia as a distinct metabolic syndrome, and growing adoption of multimodal management strategies. Cancer cachexia affects a significant proportion of patients with late-stage malignancies, and its management has become a critical component of comprehensive cancer care. Early screening for muscle wasting, appetite loss, and metabolic alterations is enabling timely intervention and improving patient quality of life.
Innovations in treatment approaches are reshaping the market landscape, with the development of novel pharmacological therapies such as anabolic agents, anti-inflammatory drugs, and appetite stimulants showing promising clinical outcomes. Ongoing research into cytokine inhibition, ghrelin receptor agonists, and metabolic modulators is further expanding therapeutic possibilities. Integration of pharmacotherapy with nutritional support, exercise programs, and palliative care is enhancing treatment effectiveness and survival outcomes.
Hospitals, oncology clinics, and palliative care centers remain the primary end users, supported by multidisciplinary treatment teams and advanced diagnostic infrastructure. Additionally, the growing focus on home-based cachexia management and oral drug formulations is improving treatment adherence and patient convenience.
Despite favorable growth drivers, the market faces challenges such as the lack of approved targeted therapies, limited awareness in developing regions, and difficulty in differentiating cachexia from other cancer-related conditions. High treatment costs and variability in patient response also pose limitations. Nevertheless, increasing clinical research investment, greater emphasis on supportive oncology care, and regulatory support for novel cachexia therapies are expected to sustain market momentum through 2032.
Market Trends
There is an increasing shift toward combination and multimodal approaches in cancer cachexia management, integrating anabolic agents, anti-inflammatory drugs, nutritional support, and physical rehabilitation to target the multifactorial nature of the condition.
According to an article published by the National Cancer Institute in October 2024, Ponsegromab (a GDF-15 inhibitor) demonstrated significant weight gain and improved appetite in cancer patients during 2023 clinical studies when used in combination with supportive care measures.
There is a growing emphasis on the development and integration of biomarker- and imaging-based diagnostic tools aimed at facilitating early detection and intervention in cancer cachexia. These advanced technologies enable clinicians to identify metabolic dysfunction, systemic inflammation, and skeletal muscle degradation at subclinical stages—well before severe weight loss and muscle wasting become apparent. Early identification allows for timely initiation of therapeutic and nutritional interventions, thereby improving treatment efficacy, enhancing patient quality of life, and potentially extending survival outcomes. This shift toward precision diagnostics represents a critical step in transforming cancer cachexia management from reactive to proactive care.
Market Opportunities
Cannabis-derived therapeutics are emerging as a potential treatment for cancer cachexia by stimulating appetite and promoting weight gain without significant psychoactive effects. Drugs like ART27.13 have shown promising results in clinical trials, helping patients maintain or increase body weight and improve overall quality of life, representing a novel pharmacological avenue in cachexia management.
In September 2025, Artelo Biosciences announced positive interim results from the Phase 2 CAReS study, evaluating ART27.13 as a once-daily oral treatment for cancer patients with cachexia. Patients who titrated to the highest dose of 1300 micrograms demonstrated a mean weight gain of 6.38% over 12 weeks, compared to a 5.42% weight loss in the placebo group. The study also observed improvements in lean body mass, activity levels, and quality of life, with no significant adverse effects reported.
The integration of artificial intelligence (AI) in imaging diagnostics is revolutionizing the early detection of cancer cachexia. AI-driven models analyzing CT scans can identify subtle changes in muscle mass and fat distribution, enabling clinicians to detect cachexia at its onset. This early identification facilitates timely interventions, potentially improving patient outcomes and quality of life.
According to a report published by Moffitt Cancer Center in April 2025, researchers developed an AI model that analyzes CT scans to quantify skeletal muscle mass. The model integrates this data with other clinical information to predict whether a patient currently has, or is at risk of developing, cancer cachexia, providing a scalable and objective solution for early detection.
Analyst View
Key Developments
Competitive Landscape
Cancer Cachexia Market Segmentation
Regional Insights
Related Reports :